Skip to main content

CASE REPORT article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1485744
This article is part of the Research Topic Prognostic Factors for Immunotherapy and Novel Treatments in Genito-Urinary Tumors View all 4 articles

Toripalimab Plus Chemotherapy for Metastatic Muscle-invasive Bladder Cancer with a high Tumor Proportion Score (TPS): A case report

Provisionally accepted
Wei Ning Wei Ning *Pengkang Chang Pengkang Chang Ji Zheng Ji Zheng Wei Chen Wei Chen
  • Xinqiao Hospital, Shapingba, China

The final, formatted version of the article will be published soon.

    Background: Radical cystectomy (RC) combined with pelvic lymph node dissection (PLND) is the standard treatment for muscle-invasive bladder cancer (MIBC). For metastatic MIBC patients, platinum-based chemotherapy remains the first choice treatment. However, approximately 50% of patients with metastatic MIBC are ineligible for platinum-based adjuvant chemotherapy because of impaired renal function. In programmed death ligand 1 (PD-L1)-positive patients who cannot tolerate platinum-based chemotherapy, immunotherapy is recommended. Thus, a major shift is taking place in the treatment of patients with metastatic MIBC. There is currently much interest in the use of chemotherapy combined with immunotherapy and maintenance immunotherapy for the treatment of metastatic MIBC.

    Keywords: Toripalimab, chemotherapy, metastatic muscle-invasive bladder cancer, Tumor proportion score, Programmed death ligand 1

    Received: 24 Aug 2024; Accepted: 02 Dec 2024.

    Copyright: © 2024 Ning, Chang, Zheng and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Wei Ning, Xinqiao Hospital, Shapingba, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.